Venous thromboembolism is commonly defined as a situation in which blood clot forms in
blood vessels. It has two types Deep vein thrombosis (clot became in leg, groin or arm) and …

Introduction: For over 60 years vitamin K antagonists have been the mainstay of oral therapy
for treatment and prevention of venous and arterial thromboembolic disease. The …

Introduction: Venous thromboembolism is a major global health burden. Since the 1930s,
prevention of stroke and pulmonary embolism in these patients has been achieved using …

The recently introduced oral anticoagulants, dabigatran, rivaroxaban and apixaban, were
shown, in randomized controlled trials, to be at least as effective and safe as monitored …

Venous thromboembolism (VTE) is a common and preventable cause of morbidity and
mortality in hospitalized patients. Low-molecular-weight heparin, low-dose unfractionated …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the factor
Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill …

Objective: To evaluate the efficacy, safety, and clinical implication of betrixaban for
prophylaxis of venous thromboembolism (VTE) in patients with acute medical illness. Data …

The anticoagulant will be made available between August and November 2017 under the
brand name Bevyxxa, according to Portola. Betrixaban will be supplied as 40-and 80-mg …

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary
embolism, is a common and potentially preventable cause of morbidity and mortality …

Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and
Drug Administration for prophylaxis of venous thromboembolism in adult patients …